GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Panacea Life Sciences Holdings Inc (OTCPK:PLSH) » Definitions » ROA %

Panacea Life Sciences Holdings (Panacea Life Sciences Holdings) ROA % : -32.68% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Panacea Life Sciences Holdings ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Panacea Life Sciences Holdings's annualized Net Income for the quarter that ended in Mar. 2024 was $-5.78 Mil. Panacea Life Sciences Holdings's average Total Assets over the quarter that ended in Mar. 2024 was $17.70 Mil. Therefore, Panacea Life Sciences Holdings's annualized ROA % for the quarter that ended in Mar. 2024 was -32.68%.

The historical rank and industry rank for Panacea Life Sciences Holdings's ROA % or its related term are showing as below:

PLSH' s ROA % Range Over the Past 10 Years
Min: -42.78   Med: -29.8   Max: -16.68
Current: -42.36

During the past 4 years, Panacea Life Sciences Holdings's highest ROA % was -16.68%. The lowest was -42.78%. And the median was -29.80%.

PLSH's ROA % is ranked worse than
84.4% of 1083 companies
in the Drug Manufacturers industry
Industry Median: 1.54 vs PLSH: -42.36

Panacea Life Sciences Holdings ROA % Historical Data

The historical data trend for Panacea Life Sciences Holdings's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Panacea Life Sciences Holdings ROA % Chart

Panacea Life Sciences Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23
ROA %
-16.68 -17.34 -42.26 -42.78

Panacea Life Sciences Holdings Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -37.66 -40.95 -47.03 -48.13 -32.68

Competitive Comparison of Panacea Life Sciences Holdings's ROA %

For the Drug Manufacturers - Specialty & Generic subindustry, Panacea Life Sciences Holdings's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Panacea Life Sciences Holdings's ROA % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Panacea Life Sciences Holdings's ROA % distribution charts can be found below:

* The bar in red indicates where Panacea Life Sciences Holdings's ROA % falls into.



Panacea Life Sciences Holdings ROA % Calculation

Panacea Life Sciences Holdings's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-8.015/( (19.489+17.983)/ 2 )
=-8.015/18.736
=-42.78 %

Panacea Life Sciences Holdings's annualized ROA % for the quarter that ended in Mar. 2024 is calculated as:

ROA %=Net Income (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=-5.784/( (17.983+17.413)/ 2 )
=-5.784/17.698
=-32.68 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data. ROA % is displayed in the 30-year financial page.


Panacea Life Sciences Holdings  (OTCPK:PLSH) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=-5.784/17.698
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-5.784 / 4.224)*(4.224 / 17.698)
=Net Margin %*Asset Turnover
=-136.93 %*0.2387
=-32.68 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Panacea Life Sciences Holdings ROA % Related Terms

Thank you for viewing the detailed overview of Panacea Life Sciences Holdings's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Panacea Life Sciences Holdings (Panacea Life Sciences Holdings) Business Description

Traded in Other Exchanges
N/A
Address
5910 S University Boulevard, C18-193, Greenwood Village, CO, USA, 80121
Panacea Life Sciences Holdings Inc is a cannabinoid nutraceutical manufacturer and research company that produces natural pharmaceutical alternatives for consumers and pets. It manufactures and sells soft gels, gummies, tinctures, sublingual tablets, cosmetics, and other topicals.
Executives
Leslie Buttorff director, 10 percent owner, officer: CHIEF EXECUTIVE OFFICER 16194 W 45TH DRIVE, GOLDEN CO 80403
Janice Nerger director 5910 S UNIVERSITY BLVD., C18-193, GREENWOOD VILLAGE CO 80121
Nathan Joel Berman officer: CONTROLLER & PRIN ACTNG OFCR 16194 W 45TH DRIVE, GOLDEN CO 80403
22nd Century Group, Inc. 10 percent owner 8560 MAIN STREET, SUITE 4, WILLIAMSVILLE NY 14221
Harvey J Kesner 10 percent owner 65 E. 55TH STREET, NEW YORK NY 10022
Lawrence Wert director 170 NUTTALL RD, RIVERSIDE IL 60546
Chesne Derek Du officer: Chief Growth Officer 80 NE 4TH AVENUE, SUITE 28, DELRAY BEACH FL 33483
Alvaro Daniel Alberttis director 80 NE 4TH AVENUE, SUITE 28, DELRAY BEACH FL 33483
Vladislav Yampolsky director, 10 percent owner 332 PLAZA REAL, BOCA RATON FL 33432
Steven A Schwartz director 332 PLAZA REAL, BOCA RATON FL 33432
Andrew L. Johnson officer: Chief Strategy Officer 80 NE 4TH AVE. SUITE 28, DELRAY BEACH FL 33483
Emiliano Angel Aloi officer: President 510 SUNSHINE DRIVE, DELRAY BEACH FL 33444
Jonathan Gilbert director, officer: Executive Chairman 36 SYCAMORE LANE, ROSALYN HEIGHTS NY 11577
John C Price director 4721 IRONTON STREET, BUILDING A, DENVER CO 80239
Kevin James Esval director NEURO HITECH INC, ONE PENN PLAZA STE 1503, NEW YORK NY 10019

Panacea Life Sciences Holdings (Panacea Life Sciences Holdings) Headlines

From GuruFocus

Panacea Announces Letter of Intent to Acquire N7 Enterprises, Inc.

By Stock market mentor Stock market mentor 01-23-2023